Broker's call: Glenmark Pharma (Neutral)
Motilal Oswal21-02-2024
GLENMARK PHARMACEUTICALS LTD. - 532296 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Details of Analyst / Investors Meeting is attached.19-02-2024
GLENMARK PHARMACEUTICALS LTD. - 532296 - Announcement under Regulation 30 (LODR)-Earnings Call Transcript
The transcript of the Earnings Call held on Friday, February 16, 2024 for the third quarter and nine months ended December 31, 2023 has been uploaded on the Company''s website.19-02-2024
Glenmark Pharma Q3 Results Review -India Business Re-Set Drags Earnings: Motilal Oswal
Work-in progress to address the U.S. FDA issues19-02-2024
GLENMARK PHARMACEUTICALS LTD. - 532296 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome
Pursuant to the Regulation 30 and 46 read with Part A of Schedule III of the SEBI (Listing Obligations and Disclosure Requirements), Regulations 2015, we hereby confirm that we have uploaded audio recording of Q3 FY 2023-24 Earnings Call held on 16th February, 2024 on the website of the Company.16-02-2024
Glenmark Pharma zooms 10% on positive management commentary
Glenmark Pharma aims to turn cash positive by the end of the current fiscal. The drugmaker also expects respiratory and injectables to be the major contributors in FY2516-02-2024
Glenmark Pharmaceuticals Results Earnings Call for Q3FY24
Conference Call with Glenmark Pharmaceuticals Management and Analysts on Q3FY24 Performance and Outlook. Listen to the full earnings transcript.16-02-2024
Glenmark Pharmaceuticals Q3 revenue drops to 2.9 crore
Glenmark Pharma shares edge up on BSE15-02-2024
GLENMARK PHARMACEUTICALS LTD. - 532296 - Announcement under Regulation 30 (LODR)-Investor Presentation
Investor Presentation Q3 FY23-2414-02-2024
GLENMARK PHARMACEUTICALS LTD. - 532296 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we are enclosing herewith the Press Release and Management Discussion & Analysis of the Company for the Third Quarter ended December 31, 202314-02-2024